Replimune Group Inc
REPLHealthcare|Biotechnology|USA
$10.99
-0.12 (-1.08%)
Tangible Book
$2.01
Earnings Power
$1.15
Financials
Financial Snapshot
Market Cap
$923.0M
Enterprise Value
$157.3M
Revenue (TTM)
$0.00
Net Income (TTM)
$-313.9M
Cash & Equivalents
—
Net Cash/Share
$1.24
Free Cash Flow (TTM)
$-284.6M
Operating CF (TTM)
$-280.3M
Debt/Equity
0.67
Cash Runway & Burn Rate
Cash on Hand
$0.00
Quarterly Burn
$70.1M
Monthly Burn
$23.4M
Est. Runway
—
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $20.6M | $61.6M | $134.8M | $168.6M | $476.3M | $395.7M | $583.4M | $420.7M | $483.8M | $268.9M | $268.9M | |
| Operating Cash Flow | $-7.1M | $-16.0M | $-25.4M | $-60.6M | $-61.4M | $-82.2M | $-128.1M | $-185.5M | $-192.3M | $-280.3M | $-280.3M | |
| Free Cash Flow | $-7.3M | $-16.1M | $-28.0M | $-67.1M | $-63.8M | $-84.5M | $-130.3M | $-191.1M | $-198.9M | $-284.6M | $-284.6M | |
| Capital Expenditure | $-238.0K | $-136.0K | $-2.6M | $-6.5M | $-2.4M | $-2.3M | $-2.3M | $-5.7M | $-6.7M | $-4.2M | $-4.2M | |
| Financing Cash Flow | $15.0M | $54.8M | $101.4M | $100.2M | $372.5M | $6.6M | $311.3M | $16.3M | $252.4M | $66.3M | $66.3M |
R&D Spending
R&D (TTM)
$221.2M
R&D Intensity
—
R&D Growth YoY
+0.0%
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $6.9M | $13.5M | $22.2M | $38.8M | $56.8M | $79.5M | $126.5M | $175.0M | $189.4M | $221.2M | $221.2M | |
| R&D % of Revenue | — | — | — | — | — | — | — | — | — | — | — | |
| SG&A | $2.7M | $5.7M | $8.8M | $17.4M | $23.2M | $38.8M | $50.6M | $59.8M | $72.2M | $98.7M | $98.7M |
Income Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Goods Sold | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D | $6.9M | $13.5M | $22.2M | $38.8M | $56.8M | $79.5M | $126.5M | $175.0M | $189.4M | $221.2M | $221.2M | |
| SG&A | $2.7M | $5.7M | $8.8M | $17.4M | $23.2M | $38.8M | $50.6M | $59.8M | $72.2M | $98.7M | $98.7M | |
| Operating Income | $-8.2M | $-17.0M | $-28.4M | $-53.1M | $-77.1M | $-115.1M | $-174.2M | $-232.9M | $-259.9M | $-318.3M | $-318.3M | |
| Interest Expense | $0.00 | $-288.0K | $-2.6M | $-1.9M | $-3.1M | $-2.2M | $-4.2M | $-6.7M | $-7.9M | $-8.9M | $-8.9M | |
| Pretax Income | $-7.7M | $-19.7M | $-30.8M | $-52.6M | $-80.9M | $-118.0M | $-174.0M | $-215.4M | $-246.8M | $-314.5M | $-314.5M | |
| Net Income | $-7.7M | $-19.7M | $-30.8M | $-52.6M | $-80.9M | $-118.0M | $-174.3M | $-215.8M | $-247.3M | $-313.9M | $-313.9M | |
| EPS (Diluted) | -0.36 | -0.92 | -1.33 | -1.54 | -1.75 | -2.26 | -2.99 | -3.24 | -3.07 | -3.38 | -3.38 | |
| EBITDA | $-8.1M | $-19.6M | $-30.7M | $-50.2M | $-76.1M | $-113.7M | $-167.4M | $-206.1M | $-235.4M | $-302.3M | $-302.3M | |
| Shares Out. (M) | 30.84 | 30.84 | 23.20 | 34.26 | 46.25 | 52.21 | 58.21 | 66.57 | 80.56 | 92.80 | 95.59 |
Balance Sheet
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $20.6M | $17.6M | $25.7M | $59.5M | $182.5M | $105.9M | $146.6M | $74.5M | $111.1M | $209.0M | $209.0M | |
| Marketable Securities | $0.00 | $44.0M | $109.1M | $109.1M | $293.8M | $289.7M | $436.8M | $346.2M | $372.7M | $59.9M | $59.9M | |
| Total Current Assets | $22.4M | $64.7M | $141.0M | $174.3M | $483.7M | $404.0M | $592.6M | $433.7M | $495.9M | $279.1M | $279.1M | |
| Total Assets | $22.8M | $65.2M | $154.3M | $234.1M | $543.1M | $461.2M | $646.6M | $487.7M | $551.3M | $332.4M | $332.4M | |
| Total Current Liabilities | $2.0M | $5.2M | $9.9M | $11.9M | $14.5M | $20.8M | $33.8M | $40.4M | $62.4M | $58.2M | $58.2M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $9.8M | $0.00 | $0.00 | $28.6M | $44.8M | $46.4M | $83.3M | $83.3M | |
| Total Liabilities | $34.3M | $93.2M | $16.5M | $50.4M | $44.4M | $50.0M | $91.3M | $113.2M | $135.5M | $166.2M | $166.2M | |
| Stockholders' Equity | $-11.5M | $-28.1M | $137.9M | $183.7M | $498.7M | $411.2M | $555.3M | $374.5M | $415.8M | $166.2M | $166.2M | |
| Retained Earnings | $-9.2M | $-28.9M | $-59.8M | $-112.3M | $-193.2M | $-311.2M | $-485.5M | $-701.3M | $-948.6M | $-1.26B | $-1.26B |
Cash Flow Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $-7.1M | $-16.0M | $-25.4M | $-60.6M | $-61.4M | $-82.2M | $-128.1M | $-185.5M | $-192.3M | $-280.3M | $-280.3M | |
| Capital Expenditure | $-238.0K | $-136.0K | $-2.6M | $-6.5M | $-2.4M | $-2.3M | $-2.3M | $-5.7M | $-6.7M | $-4.2M | $-4.2M | |
| Free Cash Flow | $-7.3M | $-16.1M | $-28.0M | $-67.1M | $-63.8M | $-84.5M | $-130.3M | $-191.1M | $-198.9M | $-284.6M | $-284.6M | |
| Investing Cash Flow | $-238.0K | $-44.0M | $-65.9M | $-5.2M | $-188.8M | $-1.8M | $-142.5M | $97.2M | $-23.8M | $310.8M | $310.8M | |
| Financing Cash Flow | $15.0M | $54.8M | $101.4M | $100.2M | $372.5M | $6.6M | $311.3M | $16.3M | $252.4M | $66.3M | $66.3M | |
| Issuance of Stock | $0.00 | $0.00 | $103.3M | $61.9M | $286.1M | $0.00 | $187.3M | $0.00 | $155.7M | $31.1M | $31.1M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Issuance of Debt | $0.00 | $0.00 | $0.00 | $10.0M | $0.00 | $0.00 | $28.2M | $15.0M | $0.00 | $35.0M | $35.0M | |
| Payments of Debt | $0.00 | $0.00 | $0.00 | $-59.0K | $-10.1M | $-264.0K | $-365.0K | $-476.0K | $-599.0K | $-736.0K | $-736.0K | |
| Stock Based Comp. | $208.0K | $812.0K | $2.7M | $7.7M | $11.8M | $24.3M | $28.1M | $34.1M | $35.0M | $32.3M | $32.3M | |
| Net Change in Cash | $6.3M | $-3.0M | $9.2M | $34.2M | $123.0M | $-76.6M | $40.6M | $-72.1M | $36.7M | $97.9M | $97.9M |
Dilution Tracker
Shares outstanding grew 83.1% over 5 years — significant dilution
Shares Outstanding
96M
5-Year Share Growth
+83.1%
Stock Issuance (TTM)
$31.1M
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 30.84 | 30.84 | 23.20 | 34.26 | 46.25 | 52.21 | 58.21 | 66.57 | 80.56 | 92.80 | 95.59 | |
| YoY Change % | — | 0.0% | -24.8% | 47.7% | 35.0% | 12.9% | 11.5% | 14.4% | 21.0% | 15.2% | 3.0% | |
| Stock Issuance | $0.00 | $0.00 | $103.3M | $61.9M | $286.1M | $0.00 | $187.3M | $0.00 | $155.7M | $31.1M | $31.1M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $208.0K | $812.0K | $2.7M | $7.7M | $11.8M | $24.3M | $28.1M | $34.1M | $35.0M | $32.3M | $32.3M |
Margins & Profitability
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | - | |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | - | |
| EBITDA Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | - | |
| FCF Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| ROE % | 0.0% | 0.0% | -56.2% | -32.7% | -23.7% | -25.9% | -36.1% | -46.4% | -62.6% | -107.9% | -112.7% | |
| ROA % | -33.8% | -44.8% | -28.1% | -27.1% | -20.8% | -23.5% | -31.5% | -38.0% | -47.6% | -71.0% | -75.6% | |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - | - |
Valuation
P/E (TTM)At Loss
HistoricalAt Loss / At Loss / At Loss
Industry Med.27.51
P/S—
Historical— / — / —
Industry Med.9.49
P/B5.47
Historical— / — / 5.47
Industry Med.2.93
EV/EBITDA-2.53
Historical-2.53 / — / —
Industry Med.13.02
EV/Revenue—
Historical— / — / —
Industry Med.8.59
P/FCF—
Historical— / — / —
Industry Med.27.13
Intrinsic Value Models
Tangible Book
$2.01
Net Current Assets
$1.360
Net-Net Working Capital
$1.24
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PE Ratio | N/A | N/A | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | |
| PS Ratio | - | - | - | - | - | - | - | - | - | - | 0.00 | |
| PB Ratio | 0.00 | 0.00 | 3.49 | 1.99 | 2.85 | 1.95 | 1.80 | 1.34 | 1.81 | 3.81 | 5.47 | |
| EV/EBITDA | 0.00 | 0.00 | -11.31 | -4.76 | -12.85 | -3.88 | -2.86 | -0.76 | -1.46 | -1.57 | -2.53 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
—
Distress
Piotroski F-Score
1
Weak
Beneish M-Score
—
Possible Manipulator
Forward Estimates
| Metric | Current Year | Next Year | 2 Years Out |
|---|---|---|---|
| Revenue | $18.28M | $112.54M | $137.62M |
| Net Income | $-222.34M | $-148.03M | $-45.40M |
| EPS | -1.97 | -0.91 | -0.54 |
| Book Value per Share | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow per Share | 0.00 | 0.00 | 0.00 |
| Operating CF | $0.00M | $0.00M | $0.00M |